{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:20:51Z","timestamp":1789863651679,"version":"4.0.1"},"reference-count":20,"publisher":"SAGE Publications","issue":"3_suppl","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The present report celebrates the benchmarking of 100,000 MiniMed\u2122 780G system users in Europe, Middle East, and Africa (EMEA) and summarizes the major insights into the usability and outcomes of this system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Carelink Personal data (August 2020\u2013August 2023) of users living in EMEA were analyzed. Continuous glucose monitoring-based endpoints were aggregated for (1) the full cohort and (2) a 12-month longitudinal cohort. Subanalyses were done for users on optimal settings (those spending \u226595% of time with glucose target of 100\u2009mg\/dL, and \u226595% of time with active insulin time of 2\u2009h), for self-reported age groups (\u226415 and \u226556 years) and for various countries\/regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Data from 101,629 users (34 countries) were analyzed. Mean time in range (TIR) was 72.3%, glucose management indicator (GMI) was 7%, time below 70\u2009mg\/dL (TBR70) was 2.0% and time below 54\u2009mg\/dL (TBR54) was 0.4%. In terms of international targets, 59.6% of users achieved a GMI &lt;7%, 62.5% a TIR &gt;70%, 88.4% a TBR70\u2009&lt;\u20094%, and 90.0% a TBR54\u2009&lt;\u20091%. Data improved impressively in optimal setting users (TIR\u2009=\u200978.8%, and users reaching TIR &gt;70%\u2009=\u200986.3%) while safety remained (TBR70\u2009=\u20092.2% and TBR54\u2009=\u20090.4%). Data showed consistency across self-reported age groups and geographies. In the longitudinal cohort, TIR reached 75.5% in the first month and remained 73.3% or higher over the 12-month period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Over 100,000 users of the MiniMed\u2122 780G system have demonstrated consistency in achieving target control of glycemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2023.0433","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T14:37:37Z","timestamp":1708439857000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":77,"title":["Celebrating the Data from 100,000 Real-World Users of the MiniMed\u2122 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence"],"prefix":"10.1177","volume":"26","author":[{"given":"Pratik","family":"Choudhary","sequence":"first","affiliation":[{"name":"Kings College Hospital NHS Foundation Trust, London, United Kingdom."},{"name":"Leicester Diabetes Center, University of Leicester, Leicester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcelia","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-6876","authenticated-orcid":false,"given":"Tim","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorino","family":"Smaniotto","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-1795","authenticated-orcid":false,"given":"Ohad","family":"Cohen","sequence":"additional","affiliation":[{"name":"Medtronic Diabetes, Medtronic International Trading S\u00e0rl, Tolochenaz, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"NICE. NICE real-world evidence framework. 2022."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1932296820957360"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14439"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.7.821"},{"key":"e_1_3_6_6_2","unstructured":"ICER. Understanding the Context Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real World Evidence for Coverage and Formulary Decisions. 2018."},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.3019"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01768-6"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.002"},{"key":"e_1_3_6_10_2","unstructured":"FDA. Framework for FDA's real-world evidence program. 2018."},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2479"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14424"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14714"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14807"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0203"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15023"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-022-03079-9"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0319"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00212-1"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15139"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2023.0433","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:14:29Z","timestamp":1777400069000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2023.0433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":20,"journal-issue":{"issue":"3_suppl","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1089\/dia.2023.0433"],"URL":"https:\/\/doi.org\/10.1089\/dia.2023.0433","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]}}}